thassodotcom
Posted in Adverse Drug Reaction [ADR], Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Thasso Post, Theragenomic Medicine
No Comments ↓
thassodotcom
Posted in Adverse Drug Reaction [ADR], Allelic Variant, Children, Clinical Development, Congenital, Gene Therapy, Genetic Predisposition, In The Press, Personalized Medicine, Rare Diseases, Thasso Post, Theragenomic Medicine
No Comments ↓
December 12, 2018 – The application of CRISPR/Cas9 based molecular technology in the field of gene editing (or genome editing) has recently had its exploded limelight exposure for a couple of reasons. The question arises if this exposure is earned or somewhat premature.
…
thassodotcom
Posted in Genetic Background, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
Thus, FDA permits marketing, with special controls,
…
thassodotcom
Posted in New Drug Approval, Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
October 31, 2018 – The American Food and Drug Administration (FDA) recently approved Cemiplimab-Rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], Allelic Variant, Genetic Susceptibility, In The Press, Personalized Medicine, Thasso Post, Theragenomic Medicine
No Comments ↓
thassodotcom
Posted in Allelic Variant, Companion Test, New Drug Approval, Personalized Medicine, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
July 22, 2018 – The American Food and Drug Administration (FDA) just approved Ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the IDH1 gene.
…
thassodotcom
Posted in Genetic Background, Genetic Predisposition, Genetic Susceptibility, New Research, Personalized Medicine, Targeted Therapy, Thasso Post
No Comments ↓
May 15, 2018 –An increasing number of women who are diagnosed with breast cancer are opting for multigene sequencing instead of the more limited testing for only BRCA1/ BRCA2 mutations, according to a new report.
The findings come from the ICanCAre study,
…
thassodotcom
Posted in Ethnicity, Gene Expression, In The Press, New Research, Personalized Medicine, Thasso Post, Theragenomic Medicine
No Comments ↓
May 10, 2018 – A seemingly higher incidence of prostate cancer and resulting fatalities in African-American men than in European-Amcerican men has been noted for quite some time. New research published in Molecular Oncology may help explain why African American men are at a higher risk of being diagnosed with prostate cancer and a higher risk of dying from the disease compared with European American men.
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], Personalized Medicine, Thasso Post, Theragenomic Medicine
1 Comment ↓
May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class, including Saxagliptin (Onglyza),
…
Optional: Social Subscribe/Login
thasso: recent comments